Arcus Biosciences, Inc. (RCUS) FY2026 Q2 Balance Sheet

Arcus Biosciences, Inc. (RCUS) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

924,000,000 US dollars

Current assets

756,000,000 US dollars

Non-current assets

168,000,000 US dollars

Liabilities (calculated)

460,000,000 US dollars

Current liabilities

198,000,000 US dollars

Non-current liabilities

262,000,000 US dollars

Equity

464,000,000 US dollars

Marketable securities

552,000,000 US dollars

Cash and cash equivalents

150,000,000 US dollars

Receivable from collaboration partners

36,000,000 US dollars

Prepaid expenses and other current assets

18,000,000 US dollars

Long-term marketable securities

73,000,000 US dollars

Other noncurrent assets

59,000,000 US dollars

Property and equipment, net

36,000,000 US dollars

Other current liabilities

145,000,000 US dollars

Accounts payable ($12 and $24 to a related party)

34,000,000 US dollars

Deferred revenue ($11 and $35 to a related party)

19,000,000 US dollars

Other noncurrent liabilities

124,000,000 US dollars

Long-term debt

101,000,000 US dollars

Deferred revenue, noncurrent ($19 and $43 to a related party)

37,000,000 US dollars

Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding

2,169,000,000 US dollars

Accumulated deficit

negative 1,704,000,000 US dollars

Accumulated other comprehensive loss

negative 1,000,000 US dollars

Gross equity (calculated)

2,169,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.